Literature DB >> 31499251

Persistent Basal Cell Hyperplasia Is Associated With Clinical and Endoscopic Findings in Patients With Histologically Inactive Eosinophilic Esophagitis.

Kelly A Whelan1, Bridget C Godwin2, Benjamin Wilkins3, Okan U Elci4, Alain Benitez5, Maureen DeMarshall6, Medha Sharma6, Jonathan Gross2, Andres J Klein-Szanto7, Chris A Liacouras2, Evan S Dellon8, Jonathan M Spergel9, Gary W Falk6, Amanda B Muir10, Hiroshi Nakagawa11.   

Abstract

BACKGROUND & AIMS: Although eosinophil count is the standard used to monitor disease activity in patients with eosinophilic esophagitis (EoE), there are often disparities between patient-reported symptoms and eosinophil counts. We examined the prevalence of epithelial alterations, namely basal cell hyperplasia (BCH) and spongiosis, among patients with inactive EoE (eosinophil counts below 15 following therapy) and aimed to determine whether maintenance of these changes in epithelial morphology are associated with persistent clinical findings.
METHODS: Esophageal biopsies of 243 patients (mean age, 16.9 years) undergoing routine endoscopy at the University of Pennsylvania were evaluated for epithelial BCH and spongiosis. Univariable analysis was used to calculate the association between epithelial changes and symptoms as well as endoscopic findings and peak eosinophil count. We validated our findings using data from a cohort of patients at the University of North Carolina.
RESULTS: The discovery and validation cohorts each included patients with inactive EoE, based on histologic factors, but ongoing BCH and spongiosis. Ongoing BCH, but not spongiosis, in patients with inactive EoE was associated with symptoms (odds ratio, 2.14; 95% CI, 1.03-4.42; P = .041) and endoscopic findings (odds ratio, 7.10; 95% CI, 3.12-16.18; P < .001).
CONCLUSIONS: In patients with EoE, the presence of BCH might indicate ongoing disease activity, independent of eosinophil count. This might account for the persistent symptoms in patients who are considered to be in remission based on histologic factors.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epithelium; Esophagus; Inflammation; Outcome; Prognostic Factor

Mesh:

Year:  2019        PMID: 31499251      PMCID: PMC7058491          DOI: 10.1016/j.cgh.2019.08.055

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  36 in total

1.  A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease.

Authors:  Evan S Dellon; Hannah P Kim; Sarah L W Sperry; David A Rybnicek; John T Woosley; Nicholas J Shaheen
Journal:  Gastrointest Endosc       Date:  2013-11-23       Impact factor: 9.427

2.  Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites.

Authors:  Seema S Aceves; Eileen King; Margaret H Collins; Guang-Yu Yang; Kelley E Capocelli; J Pablo Abonia; Dan Atkins; Peter A Bonis; Christina L Carpenter; Evan S Dellon; Michael D Eby; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; Kendra Kocher; Jeffrey P Krischer; John Leung; Jessi Lipscomb; Paul Menard-Katcher; Vincent A Mukkada; Zhaoxing Pan; Jonathan M Spergel; Qin Sun; Barry K Wershil; Marc E Rothenberg; Glenn T Furuta
Journal:  J Allergy Clin Immunol       Date:  2018-05-29       Impact factor: 10.793

3.  Esophageal epithelial cells acquire functional characteristics of activated myofibroblasts after undergoing an epithelial to mesenchymal transition.

Authors:  Amanda B Muir; Kara Dods; Yuli Noah; Sarit Toltzis; Prasanna Modayur Chandramouleeswaran; Anna Lee; Alain Benitez; Adam Bedenbaugh; Gary W Falk; Rebecca G Wells; Hiroshi Nakagawa; Mei-Lun Wang
Journal:  Exp Cell Res       Date:  2014-08-27       Impact factor: 3.905

4.  Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States.

Authors:  Elizabeth T Jensen; Michael D Kappelman; Christopher F Martin; Evan S Dellon
Journal:  Am J Gastroenterol       Date:  2014-09-30       Impact factor: 10.864

5.  Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner.

Authors:  Alain M Schoepfer; Ekaterina Safroneeva; Christian Bussmann; Tanja Kuchen; Susanne Portmann; Hans-Uwe Simon; Alex Straumann
Journal:  Gastroenterology       Date:  2013-08-13       Impact factor: 22.682

6.  Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease.

Authors:  Lisa J Martin; James P Franciosi; Margaret H Collins; J Pablo Abonia; James J Lee; Kevin A Hommel; James W Varni; J Tommie Grotjan; Michael Eby; Hua He; Keith Marsolo; Philip E Putnam; Jose M Garza; Ajay Kaul; Ting Wen; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2015-06       Impact factor: 10.793

7.  Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis.

Authors:  Scott Pentiuk; Phillip E Putnam; Margaret H Collins; Marc E Rothenberg
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-02       Impact factor: 2.839

8.  The Six-Food Elimination Diet for Eosinophilic Esophagitis Increases Grocery Shopping Cost and Complexity.

Authors:  W Asher Wolf; Kevin Z Huang; Raquel Durban; Zahra J Iqbal; Benjamin S Robey; Farah J Khalid; Evan S Dellon
Journal:  Dysphagia       Date:  2016-08-09       Impact factor: 3.438

9.  TGF-β1-induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis.

Authors:  Renee Rawson; Tom Yang; Robert O Newbury; Melissa Aquino; Ashmi Doshi; Braxton Bell; David H Broide; Ranjan Dohil; Richard Kurten; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2016-04-08       Impact factor: 10.793

10.  Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy.

Authors:  Evan S Dellon; Olga Speck; Kimberly Woodward; Shannon Covey; Spencer Rusin; Nicholas J Shaheen; John T Woosley
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

View more
  11 in total

1.  A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.

Authors:  Evan S Dellon; Paneez Khoury; Amanda B Muir; Chris A Liacouras; Ekaterina Safroneeva; Dan Atkins; Margaret H Collins; Nirmala Gonsalves; Gary W Falk; Jonathan M Spergel; Ikuo Hirano; Mirna Chehade; Alain M Schoepfer; Calies Menard-Katcher; David A Katzka; Peter A Bonis; Albert J Bredenoord; Bob Geng; Elizabeth T Jensen; Robert D Pesek; Paul Feuerstadt; Sandeep K Gupta; Alfredo J Lucendo; Robert M Genta; Girish Hiremath; Emily C McGowan; Fouad J Moawad; Kathryn A Peterson; Marc E Rothenberg; Alex Straumann; Glenn T Furuta; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2022-05-20       Impact factor: 14.290

2.  A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.

Authors:  Evan S Dellon; Paneez Khoury; Amanda B Muir; Chris A Liacouras; Ekaterina Safroneeva; Dan Atkins; Margaret H Collins; Nirmala Gonsalves; Gary W Falk; Jonathan M Spergel; Ikuo Hirano; Mirna Chehade; Alain M Schoepfer; Calies Menard-Katcher; David A Katzka; Peter A Bonis; Albert J Bredenoord; Bob Geng; Elizabeth T Jensen; Robert D Pesek; Paul Feuerstadt; Sandeep K Gupta; Alfredo J Lucendo; Robert M Genta; Girish Hiremath; Emily C McGowan; Fouad J Moawad; Kathryn A Peterson; Marc E Rothenberg; Alex Straumann; Glenn T Furuta; Seema S Aceves
Journal:  Gastroenterology       Date:  2022-05-20       Impact factor: 33.883

3.  Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease.

Authors:  Fei Li Kuang; Michelly Sampaio De Melo; Michelle Makiya; Sheila Kumar; Thomas Brown; Lauren Wetzler; JeanAnne M Ware; Paneez Khoury; Margaret H Collins; Martha Quezado; Stefania Pittaluga; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2022-03-10

Review 4.  Mechanisms and clinical management of eosinophilic oesophagitis: an overview.

Authors:  Luc Biedermann; Alex Straumann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-10-17       Impact factor: 73.082

Review 5.  EoE disease monitoring: Where we are and where we are going.

Authors:  Bridget Godwin; Benjamin Wilkins; Amanda B Muir
Journal:  Ann Allergy Asthma Immunol       Date:  2019-12-09       Impact factor: 6.347

Review 6.  Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

Authors:  Seema Aceves; Margaret H Collins; Marc E Rothenberg; Glenn T Furuta; Nirmala Gonsalves
Journal:  J Allergy Clin Immunol       Date:  2019-11-20       Impact factor: 10.793

7.  Mast Cell Infiltration Is Associated With Persistent Symptoms and Endoscopic Abnormalities Despite Resolution of Eosinophilia in Pediatric Eosinophilic Esophagitis.

Authors:  Scott M Bolton; Amir F Kagalwalla; Nicoleta C Arva; Ming-Yu Wang; Katie Amsden; Hector Melin-Aldana; Evan S Dellon; Paul J Bryce; Barry K Wershil; Joshua B Wechsler
Journal:  Am J Gastroenterol       Date:  2020-02       Impact factor: 12.045

Review 8.  Pediatric eosinophilic esophagitis: a review for the clinician.

Authors:  Antonella Cianferoni; Elio Novembre; Simona Barni; Stefania Arasi; Carla Mastrorilli; Luca Pecoraro; Mattia Giovannini; Francesca Mori; Lucia Liotti; Francesca Saretta; Riccardo Castagnoli; Lucia Caminiti
Journal:  Ital J Pediatr       Date:  2021-11-22       Impact factor: 2.638

Review 9.  Pathophysiology of Dysphagia in Eosinophilic Esophagitis: Causes, Consequences, and Management.

Authors:  Edward Young; Hamish Philpott
Journal:  Dig Dis Sci       Date:  2022-03-01       Impact factor: 3.199

10.  Image Analysis of Eosinophil Peroxidase Immunohistochemistry for Diagnosis of Eosinophilic Esophagitis.

Authors:  Benjamin L Wright; Alfred D Doyle; Kelly P Shim; Rish K Pai; Suzanne M Barshow; Jennifer L Horsley-Silva; Huijun Luo; Matthew A Rank; Elizabeth A Jacobsen; David A Katzka; Hirohito Kita; Evan S Dellon
Journal:  Dig Dis Sci       Date:  2020-04-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.